SCHEMBL13440546

SCHEMBL13440546

Cc1cc2oc(=O)cc(O)c2c(=O)n1Cc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.61
KMT2A Q03164 4/20 0.61
POLB P06746 3/20 0.61
MEN1 O00255 3/20 0.61
NPSR1 Q6W5P4 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
NOTUM Q6P988 1/20 0.47
KDM4E B2RXH2 2/20 0.46
MAPK1 P28482 3/20 0.46
TSHR P16473 2/20 0.46
ALOX15 P16050 1/20 0.46
HPGD P15428 2/20 0.44
GAA P10253 1/20 0.44
PPARG P37231 1/20 0.44
HTT P42858 1/20 0.44
MAPK10 P53779 1/20 0.44
NCOA2 Q15596 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13442525 0.89 ALDH1A1 (0.48) ALDH1A1KMT2APOLBMEN1NPSR1
SCHEMBL13442428 0.88 ALDH1A1 (0.49) ALDH1A1KMT2APOLBMEN1NPSR1
SCHEMBL13442633 0.87 KMT2A (0.51) ALDH1A1KMT2APOLBMEN1NPSR1
SCHEMBL13442691 0.85 SRC (0.46) ALDH1A1KMT2APOLBMEN1NPSR1
SCHEMBL13463107 0.83 NOTUM (0.48) ALDH1A1KMT2APOLBMEN1NPSR1
SCHEMBL13462976 0.81 LMNA (0.54) ALDH1A1KMT2APOLBMEN1NPSR1
SCHEMBL13442673 0.81 KMT2A (0.43) ALDH1A1KMT2APOLBMEN1NPSR1
SCHEMBL13463192 0.80 NOTUM (0.45) ALDH1A1KMT2APOLBMEN1NPSR1
SCHEMBL13442424 0.79 NOTUM (0.44) ALDH1A1KMT2APOLBMEN1NPSR1
SCHEMBL13442524 0.77 ALDH1A1 (0.43) ALDH1A1KMT2APOLBMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100069380-A1 HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF PTC THERAPEUTICS, INC. 2010-03-18 US disclosed
US-20100069380-A1 HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF PTC THERAPEUTICS, INC. 2010-03-18 US disclosed
WO-2008127274-A2 HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF PTC THERAPEUTICS, INC. (US) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069380-A1 HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF NSUN3, TARBP1, TRMT1 ALDH1A1 3494/4885KMT2A 2284/4885POLB 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.